For the year ending 2025-12-31, GH had -$140,338K decrease in cash & cash equivalents over the period. -$233,066K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | 982,021 | - | - | - |
| Cost of revenue | 337,195 | - | - | - |
| Research and development expense | 309,178 | - | - | - |
| Sales and marketing expense | 448,419 | - | - | - |
| General and administrative expense | 146,145 | - | - | - |
| Fair value adjustments of noncontrolling interest liability | - | - | - | 99,785 |
| Other segment items | 157,361 | - | - | - |
| Unrealized (gains) losses on marketable equity securities | - | - | 79,710 | -7,793 |
| Net loss | -416,277 | -436,373 | -479,449 | - |
| Depreciation and amortization | 39,736 | 42,387 | 42,881 | 35,962 |
| Operating lease costs | 33,577 | 31,133 | 29,699 | 28,585 |
| Gain on extinguishment of convertible notes | 13,672 | - | - | - |
| Contingent consideration | - | 1,010 | 110 | 4,305 |
| Stock-based compensation | 166,217 | 140,411 | 90,759 | 94,685 |
| Amortization of debt discount and debt issuance costs | - | - | - | 2,569 |
| Amortization of debt issuance costs | - | 2,581 | 2,575 | - |
| Interest income received on marketable debt securities | 7,677 | - | - | - |
| Amortization of discount on marketable debt securities | 5,877 | 6,774 | 13,552 | -4,595 |
| Unrealized and realized losses (gains) on marketable equity securities | 0 | -44,401 | - | - |
| Net loss | - | - | - | -654,588 |
| Impairment of non-marketable equity securities and other related assets | 18,582 | 0 | 29,054 | 5,261 |
| Deferred revenue | - | - | - | 9,873 |
| Other | 294 | -2,228 | 1,182 | -21 |
| Accounts receivable, net | 28,175 | 21,389 | -8,378 | -375 |
| Inventory, net | 14,792 | 9,135 | 10,350 | 20,926 |
| Prepaid expenses and other current assets, net | 6,354 | 7,691 | 4,332 | -20,444 |
| Operating lease liabilities | - | - | - | -20,228 |
| Other assets, net | -212 | 2,375 | -1,298 | -11,698 |
| Accounts payable and accrued liabilities | 52,749 | -2,820 | 88,591 | 60,328 |
| Other legal liabilities | 0 | 0 | - | - |
| Operating lease liabilities | -37,524 | -36,115 | -31,478 | - |
| Charge of in-process research and development costs with no alternative future use | - | - | - | 0 |
| Fair value adjustments of noncontrolling interest liability | - | 0 | 0 | - |
| Deferred revenue | 19,455 | 18,663 | 1,733 | - |
| Net cash used in operating activities | -184,760 | -239,858 | -324,975 | -309,463 |
| Purchases of marketable debt securities | 818,231 | 307,323 | 629,902 | - |
| Purchase of marketable debt securities | - | - | - | 303,757 |
| Maturities of marketable debt securities | 307,323 | 35,000 | 1,494,700 | - |
| Purchase of intangible assets and capitalized license obligations | - | - | - | 0 |
| Sales of marketable equity securities and other related assets | 0 | 53,600 | - | - |
| Maturity of marketable debt securities | - | - | - | 555,000 |
| Purchases of non-marketable equity securities and other related assets | 9,000 | 7,500 | 5,593 | 23,966 |
| Purchases of property and equipment | 48,306 | 35,085 | 20,486 | 77,461 |
| Other | - | - | -1,531 | - |
| Acquisition of business, net of cash acquired | 58,988 | - | - | - |
| Net cash (used in) provided by investing activities | -627,202 | -261,308 | 840,250 | 149,816 |
| Proceeds from issuance of common stock under employee stock purchase plan | 13,585 | 11,719 | 10,154 | - |
| Proceeds from issuance of common stock upon exercise of stock options | 19,223 | 3,119 | 405 | 2,625 |
| Employee taxes paid related to net share settlement of restricted stock units | 30,535 | 15,681 | 11,197 | 7,878 |
| Repurchase of treasury stock | 45,010 | - | - | - |
| Proceeds from issuance of common stock under employee stock purchase plan | - | - | - | 9,316 |
| Proceeds from reissuance of treasury stock | 87,872 | - | - | - |
| Proceeds from equity offerings | 257,128 | 0 | 493,116 | 0 |
| Payment of equity offering costs | 17,668 | 0 | 21,131 | 0 |
| Proceeds from borrowings on convertible senior notes | 402,500 | - | - | 0 |
| Payment of debt issuance costs | 24,588 | - | - | 0 |
| Purchase of convertible note hedges | - | - | - | 0 |
| Payment of contingent consideration | - | - | - | 1,065 |
| Payments made on finance lease obligations | - | - | - | 71 |
| Joint venture acquisition | - | 0 | 0 | 177,785 |
| Proceeds from unwinding of convertible note hedges | 5,030 | - | - | - |
| Tender offer issued in connection with the joint venture acquisition and acquisition related costs | - | 0 | 0 | -14,235 |
| Other | 3,596 | -153 | 6,028 | - |
| Net cash provided by (used in) financing activities | 671,133 | -996 | 477,375 | -189,093 |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 491 | -1,770 | -911 | -1,600 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -140,338 | -503,932 | 991,739 | -350,340 |
| Cash, cash equivalents and restricted cash beginning of period | 629,755 | - | - | - |
| Cash, cash equivalents and restricted cash end of period | 489,417 | - | - | - |
Guardant Health, Inc. (GH)
Guardant Health, Inc. (GH)